AMT-116

N/A

Report date: 2024/01/03 13:35:56

Base Information

Drug NameAMT-116
Drug Alias NameAMT-116
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsUpdating
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesT-Maximum Pharmaceutical (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesT-Maximum Pharmaceutical (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A